Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma-Reference-Cited by-同舟云学术

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

Published:2023-03-28 Issue:4 Volume:2 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Long Georgina V.¹,Stephen Hodi F.²,Lipson Evan J.³,Schadendorf Dirk⁴⁵,Ascierto Paolo A.⁶,Matamala Luis⁷,Salman Pamela⁷,Castillo Gutiérrez Erika⁸,Rutkowski Piotr⁹,Gogas Helen J.¹⁰,Lao Christopher D.¹¹,Janoski De Menezes Juliana¹²,Dalle Stéphane¹³,Arance Ana¹⁴,Grob Jean-Jacques¹⁵,Keidel Sarah¹⁶,Shaikh Anadil¹⁶,Sobiesk Anne Marie¹⁶,Dolfi Sonia¹⁶,Tawbi Hussein A.¹⁷

Affiliation:

1. Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney

2. Dana-Farber Cancer Institute, Boston

3. Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore

4. Department of Dermatology, University Hospital Essen, Essen, Germany

5. German Cancer Consortium, Partner Site Essen, Essen, Germany

6. Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy

7. Department of Oncology, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile

8. FAICIC Clinical Research, Veracruz, Mexico

9. Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

10. Department of Medicine, National and Kapodistrian University of Athens, Athens

11. Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan

12. Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil

13. Unit of Dermatology, Hospices Civils de Lyon, Cancer Research Center of Lyon, Pierre-Bénite, France

14. Department of Medical Oncology, Hospital Clinic Barcelona and IDIBAPS, Barcelona

15. Aix-Marseille University, CHU Timone, Marseille, France

16. Bristol Myers Squibb, Princeton, New Jersey

17. Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston

Publisher

Massachusetts Medical Society

Reference12 articles.

1. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

2. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

3. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review

4. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

5. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances on immunotherapy for osteosarcoma;Molecular Cancer;2024-09-09

2. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders;Advanced Science;2024-09-09

3. Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge;International Journal of Molecular Sciences;2024-08-31

4. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma;Journal of Clinical Oncology;2024-08-20

5. Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy;Journal of Experimental & Clinical Cancer Research;2024-08-15